Diffuse large B cell lymphoma (DLBCL) is a highly heterogeneous lymphoid neoplasm with
variations in gene expression profiles and genetic alterations, which lead to substantial …

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with variable outcomes.
Despite the majority of patients being cured with combination chemoimmunotherapy, up to …

Background MYC gene rearrangement is present in approximately 10% of aggressive B-cell
lymphomas, with half also harbouring a BCL2 gene rearrangement. Multiple retrospective …

Background Salvage immunochemotherapy followed by high‐dose chemotherapy and
autologous stem cell transplantation is the standard‐of‐care second‐line treatment for …

Diffuse large B-cell lymphoma (DLBCL) encompasses a wide variety of disease states that
have to date been subgrouped and characterized based on immunohistochemical methods …

Aberrant expression of CUL4B was identified in various types of solid cancers. Cumulative
evidences support the oncogenic role of CUL4B in cancers, including regulation of cell …

Background: Diffuse large B-cell lymphoma (DLBCL) is a high-grade non-Hodgkin
lymphoma with increased incidence among people living with HIV-infection (PLWH) …

Since the publication of the fourth edition of the World Health Organization (WHO)
Classification of Hematopoietic and Lymphoid Tumors in 2008, the authors have made …

Introduction Diffuse large B-cell lymphoma (DLBCL) is not a single entity but instead
represents a collection of interrelated malignancies having distinct molecular features …

Das diffuse großzellige B-Zell-Lymphom (DLBCL) umfasst eine Vielzahl von
Krankheitsbildern, die bisher auf der Basis immunhistochemischer Methoden in …